Shityakov Sergey, Kravtsov Viacheslav
Laboratory of Chemoinformatics, Infochemistry Scientific Center, ITMO University, Lomonosova str. 9, 191002, Saint Petersburg, Russia.
Curr Cancer Drug Targets. 2025 Apr 25. doi: 10.2174/0115680096379988250415094558.
Genome instability is a key driver of malignant progression in cancer and is char-acterized by chromoanagenesis, including spontaneous events, such as chromothripsis, chromoanasynthesis, and chromoplexy. These genome catastrophes create the heterogeneity necessary for tumor cells to adapt, evolve, and resist therapy. Ergodic anticancer therapy rep-resents a novel strategy for targeting cancer stem cells by manipulating their genome chaos. Two approaches have been proposed: ergodynamic anticancer therapy (EDAT), which en-hances genome chaos beyond a critical threshold and leads to self-destruction, and ergostatic anticancer therapy (ESAT), which suppresses chaos and limits malignant progression. This brief review explores the conceptual foundations, molecular mechanisms, and therapeutic potential of ergostatic and ergodynamic therapies in treating cancer, highlighting their role in personalized medicine.
